


Healthcare | Large Cap
Lupin Ltd demonstrates a very strong financial profile, marked by exceptional growth and profitability. The company is rapidly expanding its sales and profits, indicating strong market demand and effective business strategies. Its financial foundation is solid, with very low levels of debt, which minimizes long-term risk and provides stability. Shareholders are seeing excellent returns, and the company has no trouble covering its financial obligations. The primary area of concern is in operational efficiency. The company appears to be slow in selling its inventory and collecting payments from customers. While its strong growth is currently a major positive, these inefficiencies in managing day-to-day operations could present challenges in the future. The outlook is positive, driven by its powerful growth engine, but sustained success will depend on how it manages its operational assets.
Lupin Ltd demonstrates a very strong financial profile, marked by exceptional growth and profitability. The company is rapidly expanding its sales and profits, indicating strong market demand and effective business strategies. Its financial foundation is solid, with very low levels of debt, which minimizes long-term risk and provides stability. Shareholders are seeing excellent returns, and the company has no trouble covering its financial obligations. The primary area of concern is in operational efficiency. The company appears to be slow in selling its inventory and collecting payments from customers. While its strong growth is currently a major positive, these inefficiencies in managing day-to-day operations could present challenges in the future. The outlook is positive, driven by its powerful growth engine, but sustained success will depend on how it manages its operational assets.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
17.13
Industry Median
30.92
Large Cap Median
33.43
P/E RATIO
20.45
P/B RATIO
4.86
Industry Median
3.39
Large Cap Median
5.23
P/S RATIO
3.89
Industry Median
3.36
Large Cap Median
5.63
Others
PEG RATIO
0.00
EV/EBITDA RATIO
12.14
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹2385 as on Aug 6, 2026.
The company is demonstrating outstanding performance in terms of growth. All key indicators, including revenue, operating profit, and earnings per share, are expanding at an exceptional rate. This rapid expansion is supported by significant growth in the company's asset base. Such strong, across-the-board growth points to successful business strategies, high market demand, and a very positive outlook for continued expansion and shareholder value creation.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 8.19 | 1.44 | 20.24 | 13.48 | 23.12 |
| Operating Profit Growth Rate | -91.47 | 685.84 | 120.8 | 38.89 | 67.03 |
| Earnings Per Share (EPS) Growth | -225.4 | -128.11 | 344.55 | 71.1 | 62.28 |
| Asset Growth Rate | -7.59 | 5.31 | 4.17 | 22.01 | 32.39 |
| Net Income Growth Rate | -224.43 | -129.32 | 332.14 | 70.76 | 61.98 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Abbott India Ltd | 8.68 | 38.14 | Neutral | 1892.00 | 730.39 | 1552.00 |
| 2 | Glaxosmithkline Pharmaceuticals Ltd | 8.38 | 42.18 | Neutral | 1309.00 | 59.73 | 1036.00 |
| 3 | Alkem Laboratories Ltd | 8.08 | 29.08 | Neutral | 3005.00 | 182.76 | 2351.00 |
| 4 | Lupin Ltd | 7.84 | 20.45 | Neutral | 8816.00 | 139.24 | 5355.00 |
| 5 | Cipla Ltd | 7.62 | 30.76 | Neutral | 5883.00 | 43.51 | 3862.00 |
| 6 | Mankind Pharma Ltd | 7.61 | 52.23 | Overvalued | 3617.00 | 49.34 | 1938.00 |
| 7 | Zydus Lifesciences Ltd | 7.60 | 22.12 | Neutral | 8475.00 | 35.69 | 5124.00 |
| 8 | Laurus Labs Ltd | 7.10 | 111.18 | Neutral | 1778.00 | 13.71 | 890.00 |
| 9 | Dr Reddys Laboratories Ltd | 6.68 | 23.29 | Neutral | 6454.00 | 38.57 | 4158.00 |
| 10 | Glenmark Pharmaceuticals Ltd | 6.36 | 47.04 | Neutral | 4572.00 | -7.12 | 1362.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral